Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 24Kidney Neoplasms 10Neoplasms 9Carcinoma 6Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Carcinoma, Non-Small-Cell Lung 4Recurrence 3Neoplasm Metastasis 3Melanoma 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Lung Neoplasms 2Kidney Diseases 2Glioblastoma 2Carcinoma, Adenoid Cystic 2Breast Neoplasms 2Advanced Solid Tumors 2cT2a N0NxM0 Renal Tumor 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Solitary Fibrous Tumors 1Solid Tumors 1Solid Malignancies 1Skin Neoplasms 1Sarcoma, Alveolar Soft Part 1Salivary Gland Neoplasms 1Refractory or Recurrent Solid Tumors, Excluding CNS Tumors 1Prostatic Neoplasms 1

Interventions

Trabectedin 2Doxorubicin 2Dacarbazine 2pazopanib 1eribulin 1Sunitinib 1Nivolumab 1Methotrexate 1Ifosfamide 1Epirubicin 1Dasatinib 1Cisplatin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solitary Fibrous Tumors × Axitinib × Clear all
NCT02261207 2021-09-28

Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed
17 enrolled

Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡